Shuttle Pharmaceuticals Holdings, Inc. filed a Form S-1 registration statement for an initial public offering on 2024-09-20. It has amended it 4 times. It filed its final prospectus on 2024-10-31. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our common stock is listed on the Nasdaq Capital Market under the symbol “SHPH.” The closing price of our common stock on the Nasdaq Stock Market on February 5, 2026, was $1.57 per share.From the S-1/A filed 2026-02-11
Shares offered
We are offering up to 2,229,300 shares of our common stock, at an assumed public offering price of $1.57, which is equal to the closing price per share of our common stock on The Nasdaq Capital Market, on February 5, 2026, pursuant to this prospectus.From the S-1/A filed 2026-02-11
Use of proceeds
We intend to use the net proceeds from this offering to fund Phase II clinical trials for our lead product candidate radiation sensitizer Ropidoxuridine, including $2.8 million in payments that will be owed to Theradex Systems, Inc., the CRO supporting our Phase II clinical trials, along with up to $2.0 million for certain anticipated marketing fees.From the S-1/A filed 2025-03-05
Revenue
We will retain that status until the earliest of (a) the last day of the fiscal year which we have total annual gross revenues of $1,000,000,000 (as indexed for inflation in the manner set forth in the Jobs Act) or more;From the S-1 filed 2024-09-20
Net loss or income
The Company has not generated any revenues, incurred losses since inception and has a net loss of approximately $9.1 million and no revenues for the fiscal year ended December 31, 2024 and has working capital of approximately $0.7 million as of December 31, 2024.From the S-1/A filed 2025-03-05
Withdrawal
Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended, Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) hereby respectfully requests that the Securities and Exchange Commission consent to the withdrawal of the Company’s registration statement on Form S-1 (File No. 333-278535), together with all exhibits thereto (collectively, the “Registration Statement”).From the RW filed 2025-01-22
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-09-20 | Registration statement filed | S-1 |
| 2024-10-18 | Registration statement amended | S-1/A |
| 2024-10-31 | Final prospectus filed: the offering is priced | 424B4 |
| 2025-01-15 | Registration statement filed | S-1 |
| 2025-01-22 | Request to withdraw a registration (Form S-1) | RW |
| 2025-02-13 | Registration statement filed | S-1 |
| 2025-03-05 | Registration statement amended | S-1/A |
| 2025-08-05 | Registration statement filed | S-1 |
| 2025-11-18 | Registration statement filed | S-1 |
| 2025-12-11 | Registration statement amended | S-1/A |
| 2026-02-11 | Registration statement filed | S-1 |
| 2026-02-11 | Registration statement amended | S-1/A |
Shuttle Pharmaceuticals Holdings, Inc.'s full funding historyFounders and team
Tools for this story
Each opens in a new tab, filled in for Shuttle Pharmaceuticals Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.